Investigational drug · Phase 3
CAM-101
Also called: Elate Ocular, FD hPL
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye Disease, Dry Eye, Dry Eyes Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CAM-101"
First trial start
2026
Oct 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAM-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease
- Dry Eye
- Dry Eyes Chronic
- Dry Eye Syndromes
Approved drugs for the same conditions: Dry eye disease · Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "CAM-101" as an intervention, largest first.
- Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry EyePivotal-lookingNot yet recruiting
Cambium Bio LimitedIndustry
NCT06903611 · 475 participants (planned) · Start Oct 1, 2026 · Primary completion Nov 30, 2027
Drug: CAM-101 · For: Dry Eye Disease; Dry Eye; Dry Eyes Chronic and 1 more
Cambium Bio LimitedIndustry
NCT03414645 · 64 participants · Start May 1, 2018 · Primary completion Dec 12, 2019
Drug: CAM-101 10%; Vehicle Control and 1 more · For: Dry Eye; Graft-versus-host-disease; Ocular Discomfort
Sites: Palo Alto, California; Boston, Massachusetts; Ann Arbor, Michigan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Calcium Chloride vs. Mechanical Preparation of Fibrinogen-Depleted Human Platelet Lysate: Implications for Umbilical Cord Mesenchymal Stem Cell Culture.
Lim YT, Barathan M, Tan YL, et al. · Life (Basel) 2024
- Human platelet lysate supports SH-SY5Y neuroblastoma cell proliferation and differentiation into a dopaminergic-like neuronal phenotype under xenogeneic-free culture conditions.
Ribeiro M, Campos J, Pinho TS, et al. · Biotechnol J 2024
- Preparation of Fibrinogen-Depleted Human Platelet Lysate to Support Heparin-Free Expansion of Umbilical Cord-Derived Mesenchymal Stem Cells.
Kee LT, Lee YT, Ng CY, et al. · Biology (Basel) 2023
- A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A, Hussain M, Chamberlain W, et al. · Ophthalmol Sci 2022
Also in development for Dry Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.